01 Jul 2025

A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a nonrandomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).

Share this:

Other recent posts

An introduction to participant recruitment in clinical trials

Participant recruitment in clinical trials is more than a formality; it plays a crucial role in the success of medical research. In this short guide, we explore what participant recruitment...

A New Era in Respiratory Vaccines: The modRNA Breakthrough and the Power of Human Challenge Trials

Executive Summary As respiratory vaccines continue to impose significant burdens on healthcare systems around the world, vaccine development has entered a transformative era. This white paper explores the history of...

If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.

Stay connected

Sign up to our emails and follow us on social media to keep up to date with hVIVO.

By clicking Sign Up you're confirming that you agree with our Privacy Policy.